Urological aspects of the metabolic syndrome

Nature Reviews Urology

Volumn 8, Issue 9, 2011, Pages 483-494

  Hammarsten, Jan ^a   Peeker, Ralph ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARDIOVASCULAR DISEASE; ERECTILE DYSFUNCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOGONADISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MEDICAL CARE; METABOLIC SYNDROME X; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVERACTIVE BLADDER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REVIEW; URINARY TRACT DISEASE; URINE FLOW RATE; WAIST HIP RATIO;

ANIMALS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; URINARY BLADDER, OVERACTIVE; UROLOGIC DISEASES;

EID: 80052717911     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.112     Document Type: Review

References (146)

1. Himsworth, H. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 6, 127-130 (1936).
2. Reavan, G. M. Banting lecture. Role of insulin resistance in human disease. Diabetes 37, 1595-1607 (1988).
3. DeFronzo, R. A. & Ferrannini, E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194 (1991).
4. Haffner, S. M. et al. Prospective analysis of the insulin-resistance syndrome (Syndrome X). Diabetes 41, 715-789 (1992).
5. Reaven, G. M. Syndrome X: 6 years later. J. Int. Med. 236 (Suppl. 736), 13-22 (1994).
6. Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B. & Ladenson, P. W. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive study. J. Clin. Endocrinol. Metab. 94, 1853-1878 (2009).
7. Kahn, R., Buse, J., Ferannini, E. & Stern, M. The metabolic syndrome: time for critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48, 1684-1699 (2005).
8. Grundmark, B. et al. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol. Biomarkers Prev. 19, 2088-2096 (2010).
9. Hammarsten, J., Högstedt, B., Holthuis, N. & Mellström, D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostate Dis. 1, 157-162 (1998). (Pubitemid 128545860)
10. Hammarsten, J. & Högstedt, B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 8, 29-36 (1999). (Pubitemid 29278945)
11. Hammarsten, J. & Högstedt, B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 39, 151-158 (2001). (Pubitemid 32171181)
12. Hammarsten, J. & Högstedt, B. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand. J. Urol. Nephrol. 36, 330-338 (2002). (Pubitemid 35373619)
13. Hammarsten, J. et al. Insulin and free estradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostate Dis. 12, 160-165 (2009).
14. Hammarsten, J. & Högstedt, B. Clinical, hemodynamic, anthropometric, metabolic and insulin profile of men with high stage and high grade clinical prostate cancer. Blood Press. 13, 47-55 (2004). (Pubitemid 38455847)
15. Hammarsten, J. & Högstedt, B. Hyperinsulinemia: A prospective risk factor for lethal clinical prostate cancer. Eur. J. Cancer 41, 2887-2895 (2005). (Pubitemid 41713128)
16. Hammarsten, J., Damber, J.-E., Peeker, R., Mellström, D. & Högstedt, B. A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol. 34, 574-579 (2010).
17. Hald, T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl. 2, 69-77 (1989). (Pubitemid 20075621)
18. Deters, L. A., Costabile, R. A., Leveillee, R. J., Moore, C. R. & Patel, V. R. Benign prostatic hypertrophy. Medscape Reference [online], http://www.emedicine.com/med/topic1919.htm (2004).
19. Parsons, J. K. et al. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 91, 2562-2568 (2006). (Pubitemid 44024618)
20. Barnard, R. J., Aronson, W. J., Tymchuk, C. N. & Ngo, T. H. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes. Rev. 3, 303-308 (2002). (Pubitemid 35364690)
21. Giovannucci, E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res. 35, 694-704 (2003).
22. Chan, J. M. et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279, 563-566 (1998). (Pubitemid 28067285)
23. Parsons, J. K. et al. Metabolic factors associated with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 91, 2562-2568 (2006). (Pubitemid 44024618)
24. Nandeesha, H., Koner, B. C, Dorairajan, L. N. & Sen, S. K. Hyperinsulinemia and dyslipidaemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta. 370, 89-93 (2006). (Pubitemid 44080171)
25. Guo, L. J. et al. Association study between benign prostatic hyperplasia and primary hypertension. Zhonghua Wai Ke Za Zhi. 43, 108-111 (2005).
26. Roehrborn, C. et al. Baseline data from the Combination of Avodart and Tamsulosin (COMBAT) trial: relationships between body mass index and LUTS. BPH measures. Eur. Urol. Suppl. 5, 195 (2006).
27. Ochiai, A., Fritsche, H. A. & Babaian, R. J. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 66, 819-823 (2005). (Pubitemid 41440831)
28. Li, P. J., Zhang, X. H., Guo, L. J. & Na, Y. Q. Correlation of benign prostatic hyperplasia with hyperlipemia. Zhonghua Wai Ke Za Zhi. 43, 387-389 (2005).
29. Ozden, C. et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 51, 199-203 (2007).
30. McVary, K. T., Rademaker, A., Granville, L. L. & Gann, P. Automatic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 174, 1327-1333 (2005). (Pubitemid 41318722)
31. Ullrich, P. M., Lutgendorf, S. K. & Kreder, K. J. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology 70, 487-492 (2007).
32. Meigs, K. B., Mohr, B., Barry, M. J., Collins, M. M. & McKinlay, J. B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J. Clin. Epidemiol. 54, 935-944 (2001). (Pubitemid 32771319)
33. Rohrman, S., Smit, E., Giovannucci, E. & Platz, E. A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National health and nutrition examination Survey (NHANES III). Int. J. Obes. (Lond.) 29, 310-316 (2005). (Pubitemid 40333230)
34. Rohrman, S., Smit, E., Giovannucci, E. & Platz, E. A. Association of obesity with lower urinary tract symptoms and noncancer prostate surgery in the third national health and nutrition examination survey. Am. J. Epidemiol. 159, 390-397 (2004). (Pubitemid 38200773)
35. Kupelian, V. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J. Urol. 182, 616-625 (2009).
36. Dahle, S. E. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 168, 599-604 (2002). (Pubitemid 34793304)
37. Vikram, A., Gopabandhu, J. & Ramarao, P. Insulin-resistance and benign prostatic hyperplasia: the connection. Eur. J. Pharmacol. 641, 75-81 (2010).
38. Vikram, A., Jena, G. B. & Ramarao, P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 70, 79-89 (2010).
39. Hsing, A. W. et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J. Natl Cancer Inst. 93, 783-789 (2001). (Pubitemid 32514802)
40. Hsing, A. W., Gao, Y.-T., Chua, S. Jr, Deng, J. & Stanczyk, F. Z. Insulin resistance and prostate cancer risk. J. Natl Cancer Inst. 95, 67-71 (2003). (Pubitemid 36124297)
41. Lehrer, S., Diamond, E. J., Stagger, S., Stone, N. N. & Stock, R. G. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 50, 1-3 (2002). (Pubitemid 34044859)
42. Lehrer, S., Diamond, E. J., Stagger, S., Stone, N. N. & Stock, R. G. Serum insulin level, disease stage, prostate-specific antigen (PSA) and Gleason score in prostate cancer. Br. J. Cancer 87, 726-728 (2002). (Pubitemid 35178749)
43. Ma, J. et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 9, 1039-1047 (2008).
44. Gong, Z., Agalliu, I., Lin, D. W., Stanford, J. L. & Kristal, A. R. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 109, 1192-1202 (2007). (Pubitemid 46435400)
45. Freedland, S. J., Terris, M. K., Platz, E. A. & Presti, J. C. Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology 66, 108-113 (2005). (Pubitemid 41002197)
46. Freedland, S. J., Banez, L. L., Fitsimons, N. J. & Moul, J. W. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 12, 259-263 (2009).
47. MacInnis, R. J., English, D. R., Gertig, D. M., Hopper, J. L. & Giles, G. G. Body size and composition and prostate cancer risk Cancer Epidemiol. Biomarkers Prev. 12, 1417-1421 (2003).
48. Rodriguez, C., Freedland, S. J. & Deka, A. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 16, 63-69 (2007). (Pubitemid 46174265)
49. Lund Håheim, L., Wislöff, T. F., Holme, I. & Nafstad, P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am. J. Epidemiol. 164, 769-774 (2006). (Pubitemid 44522081)
50. Laukkanen, J. A. et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol. Biomarkers Prev. 13, 1646-1650 (2004). (Pubitemid 39331887)
51. Martin, R. M., Vatten, L., Gunnell, D., Romunstad, P. & Nilsen, T. I. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 20, 1181-1192 (2009).
52. Beebe-Dimmer, J. L., Dunn, R. L., Samma, A. V., Montie, J. E. & Cooney, K. A. Features of the metabolic syndrome and prostate cancer in African-American. Cancer 109, 875-881 (2007). (Pubitemid 46333529)
53. Beebe-Dimmer, J. L. et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 74, 185-190 (2009).
54. Tande, A. J., Platz, E. A. & Folsom, A. R. The metabolic syndrome is associated with reduced risk of prostate cancer. Am. J. Epidemiol. 164, 1094-1102 (2006). (Pubitemid 44851745)
55. Laaksonen, D. E. et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur. J. Endocrinol. 149, 601-608 (2003). (Pubitemid 38054707)
56. Laaksonen, D. E. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27, 1036-1034 (2004).
57. Haffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P. & Katz, M. S. Decreased testosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43, 599-603 (1994). (Pubitemid 24145467)
58. Freedland, S. J. & Platz, E. A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol. Rev. 29, 88-97 (2007). (Pubitemid 47229642)
59. Fowke, J. H. et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American. Prostate Cancer Prostatic Dis. 11, 264-269 (2008).
60. Ohwaki, K., Endo, F,. Muraishi, O., Hiramatsu, S. & Yano, E. Relationship between prostate-specific antigen and hematocrit: does hemodilution lead to a lower PSA concentrations in men with a higher body mass index? Urology 75, 648-653 (2010).
61. Li, Q. et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 21, 1025-1032 (2010).
62. Stocks, T., Hergens, M. P., Englund, A., Ye, W. & Stattin P. Blood pressure, body size and prostate cancer risk in Swedish construction workers cohort. Int. J. Cancer 227, 1660-1668 (2010).
63. Freedland, S. J. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 72, 1102-1105 (2008).
64. Albanes, D. et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J. Natl Cancer Inst. 101, 1272-1279 (2009).
65. Chen, C. et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103, 76-84 (2005). (Pubitemid 39665459)
66. Stattin, P. et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. Metab. 86, 1341-1345 (2001). (Pubitemid 32323026)
67. Hubbard, J. S. et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 63, 253-258 (2004). (Pubitemid 38234413)
68. Stocks, T. et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int. J. Cancer 120, 2678-2686 (2007). (Pubitemid 46651291)
69. Morley, J. E. et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46, 410-413 (1997). (Pubitemid 27172090)
70. Araujo, A. B. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 89, 5920-5926 (2004). (Pubitemid 39628393)
71. Mulligan, T., Frick, M. F., Zuraw, Q. Z., Stemhagen, A. & McWhirter, C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 60, 762-769 (2006). (Pubitemid 43881152)
72. Guay, A. T. The emerging link between hypogonadism and metabolic syndrome. J. Androl. 30, 370-376 (2009).
73. Selvin, E. et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30, 234-238 (2007). (Pubitemid 46198324)
74. Stellato, R. K. et al. Testosterone, sex hormone-binding globuline, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23, 490-494 (2000). (Pubitemid 30185792)
75. Haffner, S. M. et al. Decreased testosterone and dehydroepiandrosterone sulfat concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43, 599-603 (1994). (Pubitemid 24145467)
76. Laaksonen, D. E. et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur. J. Endocrinol. 149, 601-608 (2003). (Pubitemid 38054707)
77. Phillips, G. B., Jing, T. & Heymsfield, S. B. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 52, 784-790 (2003). (Pubitemid 36896315)
78. Simon, D. et al. interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom study. Diabetologia 35, 173-177 (1992).
79. Khaw, K. T. & Barrett-Connor, E. Blood pressure and endogenous testosterone in men: an inverse relationship. J. Hypertens. 6, 329-332 (1988).
80. Svartberg, J., von Muhlen, D., Schirmer, H., Barrett-Connor, E. & Sundfjord, J. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsö Study. Eur. J. Endocrinol. 150, 65-71 (2004). (Pubitemid 38159742)
81. Corona, G. et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int. J. Androl. 32, 720-728 (2009).
82. Niskanen, L. et al. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes. Metab. 6, 208-215 (2004). (Pubitemid 38559701)
83. Cohen, P. G. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med. Hypotheses 70, 358-360 (2008). (Pubitemid 350297595)
84. Vermeulen. A., Kaufman, J. M., Deslypere, J. P. & Thomas, G. Attenuated luteinizing hormone (LH) pulse amplitude but normal pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J. Clin. Endocrinol. Metab. 76, 1140-1146 (1993). (Pubitemid 23155426)
85. Cohen, P. G. The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. Med. Hypotheses 50, 331-333 (1998). (Pubitemid 28231010)
86. Zumoff, B., Miller, L. K. & Strain, G. W. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52, 1126-1128 (1993).
87. Rosmond, R., Dallman, M. F. & Björntorp, P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 83, 1853-1859 (1998). (Pubitemid 28496305)
88. Chrousos, G. P. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann. NY Acad. Sci. 851, 311-335 (1998).
89. Stamatelou, K. K., Francis, M. E., Jones, C. A., Nyberg, L. M. Jr & Curhan, G. C. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 63, 1817-1823 (2003). (Pubitemid 36513328)
90. Sakhaee, K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 75, 585-595 (2009).
91. Gorbachinsky, I., Akpinar, H. & Assimos, D. G. Metabolic syndrome and urologic diseases. Rev. Urol. 12, 157-180 (2010).
92. Cameron, M. A., Maalouf, N. M., Adams-Huet, B., Moe, O. W. & Sakhaee, K. Urine composition in type 2 diabetes. Predisposition to uric acid nephrolithiasis. J. Am. Soc. Nephrol. 17, 1422-1428 (2006). (Pubitemid 43673423)
93. Pak, C. Y. et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology 61, 523-527 (2003). (Pubitemid 36297072)
94. Taylor, E. N., Stampfer, M. J. & Gurhan, G. C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 68, 1230-1235 (2005). (Pubitemid 43246441)
95. Domingos, F. & Serra, A. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol. Dial. Transplant 26, 864-868 (2011).
96. Hamano, S. et al. Kidney stone disease and risk factors for coronary heart disease. Int. J. Urol. 12, 859-863 (2005). (Pubitemid 41726955)
97. Taylor, E. N., Stampfer, M. J. & Gurhan, G. C. Obesity, weight gain, and the risk of kidney stones. JAMA 293, 455-462 (2005).
98. Rendina, D. et al. Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension, and abdominal obesity. Nephrol. Dial. Transplant. 24, 900-906 (2009).
99. Curhan, G. C., Willett, W. C., Rimm, E. B., Speizer, F. E. & Stampfer, M. J. Body size and risk of kidney stones. J. Am. Soc. Nephrol. 9, 1645-1652 (1989).
100. Cappuccio, F. P. et al. A prospective study of hypertension and the incidence of kidney stones in men. J. Hypertens. 17, 1017-1022 (1999). (Pubitemid 29322191)
101. Obligado, S. H. & Goldfarb, D. S. The association of nephrolithiasis with hypertension and obesity: a review. Am. J. Hypertens. 21, 257-264 (2008). (Pubitemid 351323276)
102. West, B. et al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am. J. Kidney Dis. 51, 741-747 (2008). (Pubitemid 351626247)
103. Chapple, C. R. & Roehrborn, C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur. Urol. 49, 651-659 (2006).
104. Irwin, D. E. et al. Population-based survey of urinary incontinence, overactive bladder, and lower urinary tract symptoms in five countries. Results of the EPIC study. Eur. Urol. 50, 1306-1325 (2006).
105. Le, K.-A. & Tappy, L. Metabolic effects of fructose. Curr. Opin. Clin. Nutr. Metab. Care 9, 469-475 (2006). (Pubitemid 44097820)
106. Lee, W.-C., Chien, C.-T., Yu, H.-J. & Lee, S.-W. Bladder dysfunction in rats with metabolic syndrome induced by long-term fructose feeding. J. Urol. 179, 2470-2476 (2008).
107. Tong, Y.-C. & Cheng, J.-T. Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. J. Urol. 178, 1537-1542 (2007). (Pubitemid 47368379)
108. Brown, J. S. et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet. Gynecol. 94, 66-70 (1999). (Pubitemid 29284428)
109. Danforth, K. N., Townsend, M. K., Curhan, G. C., Resnik, N. M. & Grodstein, F. Type 2 diabetes mellitus and risk of stress, urge and mixed urinary incontinence. J. Urol. 181, 193-197 (2009).
110. Tai, H. C. et al. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J. Clin. Endocrinol. Metab. 95, 1143-1150 (2010).
111. Lawrence, J. M., Lukacz, E. S., Amy Liu, I.-L., Nager, C. W. & Luber, K. M. Pelvic floor disorders, diabetes, and obesity in women. Diabetes Care 30, 2536-2541 (2007).
112. Hong, G. S., Shim, B. S., Chung, W. S. & Yoon, H. Correlation between metabolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: A single institutional study. Korean J. Urol. 51, 631-635 (2010).
113. Aslan, G. et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch. Androl. 52, 155-162 (2006).
114. Irwin, D. E. et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J. Sex Med. 5, 2904-2910 (2008).
115. Dallosso, H. M., McGrother, C. W., Matthews, R. J. & Donaldson, M. M. K. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 92, 69-77 (2003). (Pubitemid 36843031)
116. Feldman. H. A. et al. Impotence and its medical and psychosocial correlates: results from the Massachusetts Male Aging Study. J. Urol. 151, 54-61 (1994). (Pubitemid 24046934)
117. McKinlay, J. B. The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res. 12 (Suppl. 4), S6-S11 (2000).
118. Aslan, Y. et al. Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome. Urology 74, 561-565 (2009).
119. Saigal, C. S., Wessels, H., Pace, J., Schonlau, M. & Wilt, T. J. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch. Intern. Med. 166, 207-212 (2006). (Pubitemid 43144945)
120. Demir, T. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int. J. Urol. 13, 385-388 (2006). (Pubitemid 43827989)
121. Bal, K. et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 69, 356-360 (2007). (Pubitemid 46274920)
122. El-Sakka, A. I. & Morsy, A. M. Screening for ischemic heart disease in patients with erectile dysfunction: role of penile Doppler ultrasonography. Urology 64, 346-350 (2004). (Pubitemid 39092468)
123. El Sakka, A. I., Morsy, A. M., Fagih, B. I. & Nassar, A. H. Coronary artery risk factors in patients with erectile dysfunction. J. Urol. 172, 251-254 (2004).
124. Jackson, G. Sexual response in cardiovascular disease. J. Sex Res. 46, 233-236 (2009).
125. Al-Hunayan, A., Al-Mutar, M., Kehind, E. O., Thalib, L. & Al-Ghorory, M. The prevalence and predictors of erectile dysfunction in men with newly diagnosed with type 2 diabetes mellitus. BJU Int. 99, 130-134 (2007). (Pubitemid 44915634)
126. Tomada, N., Tomada, I., Botelho, F., Cruz, F. & Vendeira, P. Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment. J. Sex Med. 8, 831-839 (2011).
127. Kupelian, V., Shabsig, R., Araujo, A. B., O'Donell, A. B. & McKinlay, J. B. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts male aging study. J. Urol. 176, 222-226 (2006). (Pubitemid 43815376)
128. Corona, G. et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction Int. J. Androl. 32, 720-728 (2009).
129. Reilly, C. M., Zamorano, P., Stopper, V. S. & Mills, T. M. Androgenic regulation of NO availability in rat penile erection. J. Androl. 18, 110-115 (1997). (Pubitemid 27204219)
130. Shamloul, R. et al. Correlation between penile duplex findings and stress electrocardiography in men with erectile dysfunction. Int. J. Impot. Res. 16, 235-237 (2004). (Pubitemid 38858955)
131. Blumentals, W. A., Gomez-Caminero, A., Joo, S. & Vannappagari, V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int. J. Impot. Res. 16, 350-353 (2004). (Pubitemid 39273762)
132. Chen, C. J., Kuo, T. B., Tseng, Y. J. & Yang, C. C. Combined cardiac sympathetic excitation and vagal impairment in patients with non-organic erectile dysfunction. Clin. Neurophysiol. 120, 348-352 (2009).
133. Kirby, R. S., O'Leary, M. P. & Carson, C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. 95, 103-109 (2005). (Pubitemid 350020880)
134. De Rose, A. F. et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol. Int. 68, 95-98 (2002). (Pubitemid 34136863)
135. Liguori, G. et al. Efficacy of combined oral therapy with tadalafil and alfuzosin: an integrated approach to management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J. Sex Med. 6, 544-552 (2009).
136. Kaplan, S. A., Gonzeles, R. R. & Te, A. E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur. Urol. 51, 1717-1723 (2007). (Pubitemid 46634750)
137. Rosen, R. et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (M-SAM-7). Eur. Urol. 44, 637-649 (2003). (Pubitemid 37542920)
138. McVary, K. T. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathphysiology. BJU Int. 97 (Suppl. 2), 23-28 (2006).
139. Faris, J. E. & Smith, M. R. Metabolic sequele associated with androgen deprivation therapy for prostate cancer. Curr. Opin. Endocrinol. Diabetes Obes. 17, 240-246 (2010).
140. Li, C. et al. Trends in hyperinsulinemia among nondiabetic adults in the US. Diabetes Care 29, 2396-2402 (2006).
141. Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001). (Pubitemid 32378388)
142. Friedenreich, C. M., Neilson, H. K. & Lynch, B. M. State of the epidemiological evidence on physical activity and cancer prevention. Eur. J. Cancer 46, 2593-2604 (2010).
143. Jönsson, T. et al. A paleolithic diet confers higher insulin sensitivity, lower C-reactive protein and lower blood pressure than a cereal based diet in domestic pigs. Nutr. Metab. (Lond.) 3, 39 (2006).
144. Lindeberg, S. et al. A Palaeolithical diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischemic heart disease. Diabetologia 50, 1795-1807 (2007). (Pubitemid 47222843)
145. Frassetto, L. A., Schloetter, M., Mietus-Synder, M., Morris, R. C. Jr & Sebastian, A. Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet. Eur. J. Clin. Nutr. 63, 947-955 (2009).
146. Acheson, K. J. Carbohydrate for weight and metabolic control: where do we stand? Nutrition 26, 141-145 (2010).